Table 3. Statistical correlation between demographic, clinical, pathological data, and gene mutations.
| Wild type (n=68) | Mutations (n=9) | P-value | |
|---|---|---|---|
| Age, mean±s.d. (years) | 66±21 | 67±12 | 0.89 |
| Gender (male proportion) | 49/68 | 8/9 | 0.491 |
| Previous cancer | 5/68 | 2/9 | 0.385 |
| Asbestos exposure |
44/68 |
6/9 |
0.799 |
|
Histological subtype | |||
| Epithelial | 54/68 | 5/9 | 0.241 |
| Biphasic | 7/68 | 3/9 | 0.135 |
| Sarcomatoid |
7/68 |
1/9 |
0.623 |
|
ECOG score | |||
| 0–2 | 60/68 | 8/9 | 0.892 |
| >2 |
8/68 |
1/9 |
0.617 |
|
Clinical stage | |||
| II | 37/68 | 4/9 | 0.689 |
| III–IV |
31/68 |
5/9 |
0.576 |
|
Treatment type | |||
| None | 13/68 | 1/9 | 0.623 |
| Platinum | 19/68 | 3/9 | 0.876 |
| Platinum+pemetrexed | 36/68 | 5/9 | 0.776 |
Abbreviations: ECOG=Eastern Cooperative Oncology Group; s.d.=standard deviation.